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treatment-related mortality (Figure 1, p¼0.119).
Conclusion: Late GI complications are common after HSCT,
with 18% of patients requiring endoscopy after Day 100. Few
clinical characteristics distinguish GVHD from other etiol-
ogies and endoscopy is essential to establishing the diag-
nosis. Findings of crypt destructionmay predict severe GVHD
and need for TPN.
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Introduction: Hematopoietic stem cell transplantation
(HSCT) still remains the only curative treatment for patients
suffering from severe forms of sickle cell disease (SCD). The
aim of this studywas to review the indications and outcomes
of SCD children transplantedwith a matched sibling donor at
a medium sized pediatric institution in Canada.
Methods: From 2003 to 2014, 17 children received a HSCT at
our institution. Data were retrospectively extracted from
medical charts.
Results: All children had severe forms of SCD including
stroke (3/17), silent strokes (7/17), cerebral artery stenosis
(9/17), acute chest syndrome (10/17), splenic sequestration
(5/17) and recurrent vaso-occlusive crisis requiring up to 41
hospital admissions for one patient. Neurocognitive impair-
ment was documented for 7 out of 11 children tested. Before
HSCT, 10/17 children had been treated by programmed blood
transfusions and 12/17 had received hydroxyurea. Children
transplanted after 2010 tended to be younger and to have
less brain damage. The median age at HSCT was 10y (2 to15y). The myeloablative conditioning regimen was based on
Busulfan, Cyclophosphamide and rabbit antithymoglobulin.
The source of stem cells was a bone marrow for 11 patients
and a cord blood for 6.
The median follow-up was 56 months (128 to 4m). All
patients engrafted. Stable mixed chimerism (less than 95% of
donor cells) was common (13/17). No patient experienced
new onset of SCD complications. Previous organ damages did
not progress after HSCT. No grade 2-4 acute graft versus host
disease (GVHD) was observed. Extensive chronic GVHD was
noted for 2 out of 16 patients and evolved favorably on
treatment. At 12 months after HSCT, 10 out of 11 children
were free from immunosuppressive drugs. Opportunistic
infections were common such as CMV (12/17) or EBV (13/13),
and evolved favorably with or without treatment. One death
not related to HSCToccurred 42 months after HSCT. Among 5
evaluable women, 2 have primary amenorrhea, 2 have some
signs of ovarian insufﬁciency and the youngest one (5 years
old at HSCT) has a normal ovarian function.
Conclusion: HSCT with a matched sibling donor is safe and
effective to cure children suffering from SCD, whatever the
graft source is a bone marrow or a cord blood. The outcomes
at our medium-sized Canadian institution are identical to the
best results from larger institutions. A younger age at HSCT
may enhance the functional prognosis of severe SCD and may
decrease the risk of long term gonadal toxicity related to HSCT.456
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Background: Ruxolitinib (Rux) is a potent, oral JAK inhibitor
that is approved for treatment of intermediate- or high-risk
myeloﬁbrosis (MF). Several groups reported on Rux use
before alloSCT with primary goals of splenomegaly and
constitutional symptom reduction. There are no data on Rux
posttransplant.
Methods: We retrospectively analyzed the outcomes of pa-
tients diagnosed with MF at University of Massachusetts
Medical Center who received Rux before and post alloSCT
(between 6/2013 and 8/2014).
Results: Four patients (2 females)were identiﬁed;median age
was76 years (49-83) at diagnosis. One patient had primaryMF,
3 had secondaryMF. Onehad secondaryAMLwithpost PV-MF,
1 had secondary MDS with MF and one had chronic myelo-
monocytic leukemiawithMF. All had constitutional symptoms
at diagnosis. Three patients had splenomegaly, 1 had surgical
splenectomy before alloSCT. Three patients had received Rux
before alloSCT. The median time from Rux to alloSCT was 4
months (0.4-4.9). Two patients received RIC regimen (Flu-
darabine/Bu2/ATG) and 2 received Thiotepa/Fludarabine/
Melphalan with posttransplant cyclosphosphamide. Neutro-
phils engraftedwithmedian 16 days (12-23). All patientswere
transfusion independent at day 30 (D30) with >97% donor
chimerism in BM. Following the alloSCT Rux was started with
median 2.2 months (0.4-8.8) from alloSCT. CMV viremia was
detected in one patient before day 100 and one had suspected
VZV reactivation at 12 months, in both cases Rux was
continued. No EBV reactivation or fungal infection was seen.
Three pts had a brief episode of aGVHD (grade I, I and III) of the
skin that responded to steroids and immunosuppression taper.
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median post SCT survival of 9.4 months (2.1-18.5).
Conclusion: Posttransplant Rux appears to be safe and
feasible. Further investigation is warranted to elucidate
whether improved outcomes are due to a direct effect on the
primary marrow disorder, alleviation of the constitutional
symptoms or GvHD.Figure.457
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Background: Primary graft failure (pGF) after cord blood
transplantation (CBT) still occurs in roughly 10% of cases.
Although associated with a poor prognosis, cases diagnosed
early have an increased possibility of rescue with re-trans-
plantation. We considered an early stage diagnostic method
by elucidating mechanisms underlying post-CBT pGF.
Patients and Method: We analyzed 105 cases of single-unit
CBT at our institution. For pGF cases, we analyzed WBC dy-
namics (neutrophils, lymphocytes), chimerism, and fever,
and compared these parameters with delayed (>day 28) or
normal (day 28) engraftment cases.
Results: Of the evaluable 102 cases, 59 were normal engraft-
ment cases, 33 were delayed engraftment cases, and 10 were
pGF cases. Of the 10 pGF cases, 7 showed essentially no blood
cell count recoverybyday14, andsudden lymphocyte recovery
at amedian of day 18 (range,15-24) followedbygraft rejection.
Of the 4 assessed for chimerism at the time of lymphocyte in-
crease, all showed recipient-derived cells. 3 of the 10 pGF cases
never achievedWBC100/mL byday28. For engraftment cases,
lymphocyte number peaked at day 12, and almost cases
assessed for chimerism showed donor-derived cells. Only 1 of
the 67 cases which showedWBC>100/mL on day 12 indicated
pGF, whereas pGF was observed in 9 of the 33 cases in which
WBC was <100/mL (p<0.001). 72 cases had febrile episodes
which were associated with pre-engraftment immune reac-
tion. Theproportionof febrile (38C)casespeakedatday8 for
normal engraftment cases, day 11 for delayed engraftment
cases, and day 12.5 for pGF cases.
Conclusions: pGF likelihood should be considered for cases
of delayed timing of non-infectious fever, cases for which
WBC recovery is not seen at around day 12, and cases of
sudden lymphocyte recovery at around day 18.Table.
Age Sex Disease Prior
Auto
N prior
therapies
Status at
transplant
Donor CD34 dose 1
(x10e6/kg)
CD
(x
41 M FL Yes 4 CR MRD 3.18
87 M DLBCL Yes 3 PO MUD 1.9
64 M DLBCL No 2 PR MUD 1.84
54 F MCL No 2 PR MUD 10.19
52 M DLBCL Yes 4 PR MRD 2.94
69 M FL Yes 5 PR MUD 10.39
39 M DLBCL No 2 PR MUD 6.87
35 F DLBCL No 2 PR MRD 5.87
61 M DLBCL No 2 CR MMRD 7.9
46 F DLBCL No 1 CR MMUD 4.03 11458
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A subset of patients with advanced or relapsed B-cell lym-
phomas can be cured with allogeneic hematopoietic cell
transplantation (allo-HCT), but success is hampered by the
risk of recurrence and GVHD. Here we report the results of a
phase 2, single center trial combining anti-CD20 radio-
immunotherapy (RIT) with I-131 tositumomab and mTOR
inhibitionwith sirolimus for prevention of serious GVHD and
reduction in risk of relapse. Subjects (n¼10) received I-131
tositumomab 75cGi therapeutic dose on day -12, ﬂudarabine
25 mg/m2 IV on days -6 to -2 and melphalan 70 mg/m2 IV on
days -3 and -2 followed by peripheral blood grafts from 7/8
or 8/8 HLA matched related or unrelated donors. GVHD
prophylaxis consisted in sirolimus 12 mg PO loading dose on
day -14 in order to overlap with the conditioning regimen,
then 4mg PO daily with target blood level of 3-12 ng/ml, and3 dose
10e8/kg)
aGVHD
max
grade
cGVHD Time of
relapse
(months)
Follow-up
(months)
Outcome
3.38 3 Yes 8.9 18.4 Death from disease
0.3 0 Yes 63.6 Alive
2.97 0 Yes 60.8 Alive
3.57 0 Yes 10.2 Death from PE
4.22 0 Yes 9.3 33.0 Death from disease
1.61 0 Yes 13.6 25.1 Alive
2.24 0 No 17.1 18.0 Alive after relapse
3.01 0 No 4.5 14.0 Alive after relapse
3.01 0 Yes 9.8 Alive
2 0 Yes 8.9 Alive
